Accrelist (SGX:QZG) Research & Development: S$0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Accrelist Research & Development?

Accrelist SGX:QZG -5.80% Research & Development is S$0.00 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Accrelist's Research & Development for the six months ended in Mar. 2026 was S$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was S$0.00 Mil.

Accrelist  (SGX:QZG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Accrelist Research & Development Related Terms

Accrelist Research & Development Historical Data

* Premium members only.

The historical data trend for Accrelist's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accrelist Research & Development Chart

Accrelist Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Accrelist Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Accrelist Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of S$0.00 Mil mean?
Accrelist (SGX:QZG) has a Research & Development of S$0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Accrelist and its competitors.
Is Accrelist's Research & Development too high?
Accrelist's current Research & Development is S$0.00 Mil.
How does Accrelist's Research & Development compare to HCA and THC?
Accrelist's Research & Development of S$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Accrelist and its competitors. Accrelist's current Research & Development is S$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accrelist stock overvalued right now?
Based on GuruFocus' analysis, Accrelist (SGX:QZG) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.04, compared to a current price of S$0.07 — trading 62.5% above its estimated fair value. The current Research & Development is S$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Accrelist (SGX:QZG), the current Research & Development is S$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accrelist Business Description

Address 10 Ubi Crescent, Ubi Techpark, Lobby E No. 03-95, Singapore, SGP, 408564
Accrelist Ltd is focused on the distribution of electronics components, plastic injection molding, mold design, and fabrication services. The company's segment comprises a Mechanical business unit (MBU), Aesthetic Medical Services (AMS), and others. Accrelist is focused on maintaining a diversified customer mix and product portfolio for MBU and EBU while continuing to expand upon the medical aesthetic products and services provided to consumers. it generates a vast majority of revenue from the MBU segment.